News
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.
The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...
The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...
Gilead has plans for a rapid launch in the United States as well as a wider rollout of the drug in collaboration with global ...
Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent ...
The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly ...
In two recent studies, this new shot reportedly nearly eliminated new infections in people at substantial risk of HIV.
FDA approves Gilead Sciences' groundbreaking HIV prevention injection, Yeztugo, with 99.9% effectiveness, but high cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results